Clearmind Medicine Inc. Common Shares
Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It d… Read more
Market Cap & Net Worth: Clearmind Medicine Inc. Common Shares (CMND)
Clearmind Medicine Inc. Common Shares (NASDAQ:CMND) has a market capitalization of $1.35 Million ($1.35 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #41069 globally and #13341 in its home market, demonstrating a -26.47% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Clearmind Medicine Inc. Common Shares's stock price $0.75 by its total outstanding shares 1794806 (1.79 Million).
Clearmind Medicine Inc. Common Shares Market Cap History: 2021 to 2026
Clearmind Medicine Inc. Common Shares's market capitalization history from 2021 to 2026. Data shows change from $823.82 Million to $1.35 Million (-76.95% CAGR).
Index Memberships
Clearmind Medicine Inc. Common Shares is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #925 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #2883 of 3165 |
Weight: Clearmind Medicine Inc. Common Shares's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Clearmind Medicine Inc. Common Shares Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Clearmind Medicine Inc. Common Shares's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CMND by Market Capitalization
Companies near Clearmind Medicine Inc. Common Shares in the global market cap rankings as of March 18, 2026.
Key companies related to Clearmind Medicine Inc. Common Shares by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Clearmind Medicine Inc. Common Shares Historical Marketcap From 2021 to 2026
Between 2021 and today, Clearmind Medicine Inc. Common Shares's market cap moved from $823.82 Million to $ 1.35 Million, with a yearly change of -76.95%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.35 Million | -58.56% |
| 2025 | $3.25 Million | +31.16% |
| 2024 | $2.48 Million | -50.89% |
| 2023 | $5.04 Million | -97.04% |
| 2022 | $170.15 Million | -79.35% |
| 2021 | $823.82 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Clearmind Medicine Inc. Common Shares was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.35 Million USD |
| MoneyControl | $1.35 Million USD |
| MarketWatch | $1.35 Million USD |
| marketcap.company | $1.35 Million USD |
| Reuters | $1.35 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.